Post Profile

AstraZeneca licenses inflammatory disease candidate to Allergan

LONDON (Reuters) - Britain's AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.
read more


Related Posts

AstraZeneca sells rights to anaesthetics to South Africa's Aspen

Business & Finance : Business Insider: Clusterstock

LONDON (Reuters) - AstraZeneca said on Thursday it had agreed to sell the commercialisation rights for its portfolio of anaesthetics outside the United States to South Africa's Aspen Pharmacare for an initial payment of $520 million...

Inflammatory Bowel Disease More Than Doubles Potentially Fatal Blood Clot Risk

Health : Medical News Today

Inflammatory bowel disease more than doubles the risk of a potentially fatal blood clot in the legs or lungs (VTE), reveals research published online in the journal Gut. Inflammatory bowel disease is an umbrella term used to include...

Allergan to buy Tobira in push for fatty liver disease drugs

Health : Reuters: Health

(Reuters) - Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease ...

New International Study Investigating Inflammatory Bowel Disease

Health : Medical News Today

The University of Manchester is leading a 12 million euro systems medicine research network to identify better treatments for Inflammatory Bowel Disease like Crohn's Disease. Professor Werner Müller from the Faculty of Life Science...

Visa to buy Visa Europe in deal worth up to 21.2 billion euros

Business & Finance : Business Insider: Clusterstock

(Reuters) - Visa Inc said on Monday it would acquire Visa Europe for 16.5 billion euros ($18.19 billion), with the potential for an additional payment of up to 4.7 billion euros. The upfront payment comprises 11.5 billion euros in c...


Copyright © 2016 Regator, LLC